Protagonist Therapeutics (PTGX)
(Real Time Quote from BATS)
$31.46 USD
-0.25 (-0.79%)
Updated May 23, 2024 12:12 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
Protagonist Therapeutics, Inc. [PTGX]
Reports for Purchase
Showing records 21 - 40 ( 49 total )
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another Win for Rusfertide, This Time in Hereditary Hemochromatosis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Janssen Opts-Out of PTG-200 in Favor of 2nd Gen Assets as Value Proposition Remains Unchanged; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rusfertide Clinical Hold Lifted With Dosing to Resume Shortly; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Clinical Hold on Rusfertide Amid Tumorigenesis in Mouse Model
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IBS Assets Ready to Move Out From Rusfertides Shadow; Reiterate Buy, PT Up to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Protagonist Scores a Big Win as Janssen Looks to Accelerate IL-23 Franchise; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Update from EHA: Rusfertides Impressive Phase 2 Data Shown to Be Durable; Reit Buy Raise PT to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Update from EHA: Rusfertides Impressive Phase 2 Data Shown to Be Durable; Reit Buy Raise PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rusfertide and IBS Assets Chugging Along in Clinical Trials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Protagonist Gets Green Light for Single International PV Phase 3 from FDA and EMA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Quietly Advancing on All Fronts in the Pipeline; Reiterate Buy, PT to $36
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Investigator Call Provides Additional Insight on Positive PTG-300 Data Presented at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Update From ASH: PTG-300 Phase 2 Continues to Demonstrate Long-Term Efficacy in PV; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PTG-300 Continues to Impress in PV With More Data in Abstracts Ahead of ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Janssen Partnership Grows With Two New Molecules Set to Enter the Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An Update on the PTG-300 Opportunity; Reiterate Buy, Raise Price Target to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Protagonist Makes Steady Progress on the Pipeline From a Strong Cash Position; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PTG-300 Offers Further Evidence of Mechanism; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PTG-300 Comes up Aces in Polycythemia Vera; Reiterate Buy, Target up to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D